Predict your next investment

LSI company logo
BUSINESS PRODUCTS & SERVICES | Education & Training (business)
lsijax.com

See what CB Insights has to offer

About LSI

LSI provides training and technical support services to the U.S. Government, Foreign militaries, and the Defense Industry. The company specializes in training, maintenance training, instructional systems design, curriculum development, instructor services and training support services, virtual interactive training, training devices & simulation, technical data support, mobile applications, and manufacturing & fabrication. It is based in Jacksonville, Florida.

LSI Headquarter Location

6111 Technology Court

Jacksonville, Florida, 32221,

United States

Latest LSI News

Jubilant Pharmova's consolidated profit declines 36.2%

Oct 22, 2021

Jubilant Pharmova's consolidated profit declines 36.2% to Rs 142.8 cr in July-Sept quarter Jubilant Pharmova's consolidated profit declines 36.2% to Rs 142.8 cr in July-Sept quarter Drug firm Jubilant Pharmova on Friday reported that its net profit declined 36.24% to Rs 142.84 crore in the quarter ended September 2021 as against Rs 224.03 crore during the previous quarter ended September 2020. Jubilant Pharmova's consolidated profit declines 36.2% BusinessToday.In Updated Oct 22, 2021, 7:32 PM IST The company's sales rose 5.41 per cent to Rs 1,633.68 crore in the quarter ended September 2021 as against Rs 1549.79 crore in the last quarter ended September 2020. Its total revenue from operations is Rs 1,657 crore for Q2 FY22, compared to Rs 1,591 crore in Q2 FY21. The firm's reported EBITDA stands at Rs 344 crore compared to Rs 353 crore in Q2 FY21. Its capital expenditure was Rs 131 crore. "With the demerger of LSI business into Jubilant Ingrevia, effective February 1, 2021, the company's consolidated results for Q4'FY21 include only one month of LSI business, and consolidated results for FY21 include only ten months of LSI business. For FY21, our continuing operations, despite COVID-19 challenges, revenues were stable due to a diverse range of businesses," Shyam S Bhartia, Chairman and Hari S Bhartia, Co-Chairman and MD, Jubilant Pharmova said in a joint statement. The company's pharmaceutical segment had an increase in its YoY revenue by 2 per cent to Rs 1,543 crore in Q2 FY22. CMO (contract manufacturing org) business revenue grew 11 per cent YoY based on continued strong demand from customers and due to COVID related deals. Its radiopharma business witnessed improvement in sales YoY, however pace of recovery during the quarter was affected by an increase in COVID-19 cases in the US, the report said. The generics business had Rs 330 crore revenue in Q2FY22, compared to Rs 423 crore in Q1FY21. The company said the generics business performance was adversely affected due to pricing pressure in the US market and lower volumes due to import alert at its Roorkee plant. The company's research and development segment clocked in a revenue of Rs 108 crore, up by 44 per cent YoY on robust volume growth. TAGS:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

LSI Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

LSI Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.